JUN 20, 2017 2:37 PM PDT

A 3-in-1 Blood Test Brings Precision Medicine to Prostate Cancer

WRITTEN BY: Xuan Pham

The cancer drug olaparib was recently shown to be effective in some types of advanced prostate cancer. Now, scientists say they’ve developed a blood test that will identify the men who would likely respond to this drug. Moreover, they say the same blood test can reveal whether patients are responding or if the cancer has mutated. The “three-in-one” blood test could be one of the most powerful gene-targeted, personalized therapy for prostate cancer to date.

Image credit: Pixabay.com

Prostate cancer represents a huge health risk for half the world’s population, as it is the most common form of cancer in men. Current treatments for the disease are confined to the affected prostate tissue, commonly involving radiation and chemotherapy aimed at the cancer cells in the prostate, or surgical removal of the prostate itself. But the line of defense against prostate cancer may have strengthened dramatically with olaparib, a drug that specifically targets DNA-repair genes.

Olaparib is not a novel drug. Manufactured by Astrazeneca under the tradename Lynparza, olaparib was recently approved by the FDA as a cancer drug for ovarian cancers associated with BRCA1/2 mutations. In these types of cancers, there’s a propensity of the cancer cells to rely only on the enzyme poly ADP-ribose polymerase (PARP) to repair its constantly dividing DNA. The drug olaparib exploits this vulnerability and acts as a PARP inhibitor, effectively killing the cancer cells by allowing DNA damages to go unrepaired, while having no adverse effects on normal cells.

In a recent study by the Institute of Cancer Research in London, olaparib was given to a cohort of 49 men with treatment-resistant and metastatic prostate cancer. Within this cohort, 16 men showed tumor mutations in DNA damage-repair genes, including BRCA1/2, ATM, PALB2, CHEK2, FANCA, and HDAC2. The team reported significantly higher response rate to olaparib for these 16 men out of the group of 49, citing greater than 50% reduction in prostate specific antigen (PSA) levels, decreased prostate cancer cells, and shrinkage of secondary tumors.

To identify men who will benefit from olaparib, researchers analyzed cancer DNA circulating in the blood. Men with mutations in DNA damage-repair genes were more likely to respond to olaparib.

The team also noticed that analyzing the levels of the circulating tumor DNA after olaparib treatment could predict response. Specifically, patients who showed response to the drug had a 49.6 percent drop in the levels of circulating tumor DNA. By comparison, men who did not respond to the drug actually showed an increase of 2.1 percent in circulating tumor DNA levels. Those with a reduction in circulating tumor DNA survived an average of nearly 7 months longer.

By monitoring the patient's’ circulating tumor DNA, the team could also pick up new genetic mutations that would make the cancer resistant to olaparib. This information could prompt doctors to change course of therapy, effectively staying one step ahead of the cancer.

"From these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term. We think it could be used to make clinical decisions about whether a PARP inhibitor is working within as little as four to eight weeks of starting therapy,” said Dr. Johann de Bono, the study’s senior investigator. "Not only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well."

Through active surveillance and screening, the mortality rate for prostate cancer has dramatically been reduced. However, prostate cancer remains one of the top leading causes of cancer-related deaths for men worldwide. The current study represents a huge achievement for prostate cancer treatment, identifying olaparib as a highly targeted prostate cancer drug. The study has also added to the groundwork for future clinical therapy that’s based on individual genetic profiles.

Additional source: BBCInstitute of Cancer Research

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 11, 2020
Cancer
Targeting Senescence in the Peripheral Nervous System to Fight Toxicity
SEP 11, 2020
Targeting Senescence in the Peripheral Nervous System to Fight Toxicity
Chemotherapy is a life-saving discovery for cancer patients. One of its biggest drawbacks is the toxicity that comes wit ...
SEP 11, 2020
Cancer
Taking cancer treatment from a whole new angle
SEP 11, 2020
Taking cancer treatment from a whole new angle
New cancer research is looking at treatment for the disease from an entirely new angle: structurally. While chemotherapy ...
SEP 17, 2020
Cardiology
Can Grape Polyphenol Extracts prevent Cardiotoxicity?
SEP 17, 2020
Can Grape Polyphenol Extracts prevent Cardiotoxicity?
One of the biggest issues with chemotherapy treatments is their inherent toxicities. Most chemotherapy drugs are toxic t ...
OCT 20, 2020
Cancer
Is your physical activity intense enough?
OCT 20, 2020
Is your physical activity intense enough?
Older adults with higher physical activity and lower sitting time have better overall physical and mental health, accord ...
NOV 02, 2020
Cancer
Using an Anti-Malarial Drug to Fight Cancer
NOV 02, 2020
Using an Anti-Malarial Drug to Fight Cancer
Modern pharmaceutical companies spend billions of dollars and years of time developing the next big drug. What if they d ...
NOV 25, 2020
Cancer
Using RNA to Diagnose HPV Associated Cancer
NOV 25, 2020
Using RNA to Diagnose HPV Associated Cancer
Diagnostic tools are critical to modern medicine. They might be less exciting than a good therapy or drug, but doctors a ...
Loading Comments...